MX2012012826A - Formulaciones de galactomanana oftalmicas estabilizadas. - Google Patents
Formulaciones de galactomanana oftalmicas estabilizadas.Info
- Publication number
- MX2012012826A MX2012012826A MX2012012826A MX2012012826A MX2012012826A MX 2012012826 A MX2012012826 A MX 2012012826A MX 2012012826 A MX2012012826 A MX 2012012826A MX 2012012826 A MX2012012826 A MX 2012012826A MX 2012012826 A MX2012012826 A MX 2012012826A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- stabilized ophthalmic
- guar
- galactomannan formulations
- ophthalmic galactomannan
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 229920000926 Galactomannan Polymers 0.000 title abstract 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 title 1
- -1 hydroxypropyl Chemical group 0.000 abstract 3
- 244000007835 Cyamopsis tetragonoloba Species 0.000 abstract 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004327 boric acid Substances 0.000 abstract 1
- 150000002009 diols Chemical class 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a formulaciones oftálmicas estabilizadas de viscosidad y formulaciones oftálmicas adecuadas para suministro de fármacos. Las formulaciones comprenden galactomananas tales como goma guar o goma guar hidroxipropílica y una fuente de borato tal como ácido bórico. Las formulaciones comprenden además un alcohol de diol tal como sorbitol y, opcionalmente, una sal catiónica divalente farmacéuticamente aceptable tal como cloruro de magnesio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33151110P | 2010-05-05 | 2010-05-05 | |
| PCT/US2011/035165 WO2011140203A2 (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012012826A true MX2012012826A (es) | 2013-01-28 |
Family
ID=44626461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012012826A MX2012012826A (es) | 2010-05-05 | 2011-05-04 | Formulaciones de galactomanana oftalmicas estabilizadas. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20110275593A1 (es) |
| EP (1) | EP2566447B1 (es) |
| JP (1) | JP5794744B2 (es) |
| KR (2) | KR20130060228A (es) |
| CN (2) | CN106389325A (es) |
| AR (1) | AR081015A1 (es) |
| AU (1) | AU2011248129B2 (es) |
| BR (1) | BR112012028308B1 (es) |
| CA (1) | CA2798069C (es) |
| ES (1) | ES2809304T3 (es) |
| MX (1) | MX2012012826A (es) |
| NZ (1) | NZ603345A (es) |
| SG (2) | SG185422A1 (es) |
| TW (1) | TWI606841B (es) |
| WO (1) | WO2011140203A2 (es) |
| ZA (1) | ZA201208199B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722508C (en) * | 2008-04-26 | 2016-08-16 | Alcon Research Ltd. | Polymeric artificial tear system |
| TWI492769B (zh) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| TW201336527A (zh) * | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | 具增強的穩定性之水性藥學組成物 |
| UA113434C2 (uk) * | 2012-05-04 | 2017-01-25 | Алкон Рісерч, Лтд. | Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| EP3448389B1 (en) | 2016-06-27 | 2021-09-29 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| US11260035B2 (en) | 2016-10-12 | 2022-03-01 | Ps Therapies Ltd | Topical compositions and methods of use thereof |
| CA3039464A1 (en) * | 2016-10-12 | 2018-04-19 | Ps Therapy Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| US11583496B2 (en) | 2016-10-12 | 2023-02-21 | PS Therapy Inc. | Drug vehicle compositions and methods of use thereof |
| PL3985002T3 (pl) | 2017-03-01 | 2025-09-15 | Achillion Pharmaceuticals, Inc. | Arylowe, heteroarylowe i heterocykliczne związki farmaceutyczne do leczenia zaburzeń medycznych |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| TWI757773B (zh) * | 2019-06-28 | 2022-03-11 | 瑞士商愛爾康公司 | 眼用組成物 |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2025186703A1 (en) | 2024-03-04 | 2025-09-12 | Alcon Inc. | Carbamoylphenylboronic acid-containing acrylic monomers and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8028A (en) * | 1851-04-08 | Hokse-poweb | ||
| US4136173A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
| DE3827561C1 (es) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| US5505953A (en) * | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| ES2206965T3 (es) | 1997-07-29 | 2004-05-16 | Alcon Laboratories, Inc. | Composiciones oftalmicas que contienen polimeros de galactomanana y borato. |
| GB9808461D0 (en) * | 1998-04-22 | 1998-06-17 | Innovative Tech Ltd | Solid borate-diol interaction products |
| US7084130B2 (en) * | 2001-12-11 | 2006-08-01 | Alcon, Inc. | Intraocular irrigating solution having improved flow characteristics |
| TWI336257B (en) * | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| WO2008036855A2 (en) * | 2006-09-21 | 2008-03-27 | Alcon Research, Ltd. | Self-preserved aqueous pharmaceutical compositions |
| TWI434926B (zh) | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | 眼用組成物中聚氧化乙烯-聚氧化丁烯（ｐｅｏ-ｐｂｏ）嵌段共聚物之使用 |
| AR066901A1 (es) * | 2007-05-18 | 2009-09-23 | Alcon Mfg Ltd | Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas |
| CA2722508C (en) * | 2008-04-26 | 2016-08-16 | Alcon Research Ltd. | Polymeric artificial tear system |
| NZ594419A (en) | 2009-02-05 | 2013-07-26 | Alcon Res Ltd | Process for purifying guar |
-
2011
- 2011-05-04 EP EP11720357.0A patent/EP2566447B1/en active Active
- 2011-05-04 MX MX2012012826A patent/MX2012012826A/es active IP Right Grant
- 2011-05-04 CN CN201610986410.7A patent/CN106389325A/zh active Pending
- 2011-05-04 KR KR1020127031590A patent/KR20130060228A/ko not_active Ceased
- 2011-05-04 CN CN2011800292803A patent/CN102939074A/zh active Pending
- 2011-05-04 US US13/100,439 patent/US20110275593A1/en not_active Abandoned
- 2011-05-04 CA CA2798069A patent/CA2798069C/en active Active
- 2011-05-04 SG SG2012081386A patent/SG185422A1/en unknown
- 2011-05-04 KR KR1020177037138A patent/KR20180001587A/ko not_active Ceased
- 2011-05-04 ES ES11720357T patent/ES2809304T3/es active Active
- 2011-05-04 SG SG10201804305SA patent/SG10201804305SA/en unknown
- 2011-05-04 TW TW100115587A patent/TWI606841B/zh active
- 2011-05-04 WO PCT/US2011/035165 patent/WO2011140203A2/en not_active Ceased
- 2011-05-04 BR BR112012028308-1A patent/BR112012028308B1/pt active IP Right Grant
- 2011-05-04 JP JP2013509217A patent/JP5794744B2/ja active Active
- 2011-05-04 AU AU2011248129A patent/AU2011248129B2/en active Active
- 2011-05-04 NZ NZ603345A patent/NZ603345A/en not_active IP Right Cessation
- 2011-05-05 AR ARP110101556A patent/AR081015A1/es unknown
-
2012
- 2012-10-31 ZA ZA2012/08199A patent/ZA201208199B/en unknown
-
2013
- 2013-05-13 US US13/892,429 patent/US8846641B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2798069A1 (en) | 2011-11-10 |
| SG10201804305SA (en) | 2018-06-28 |
| CA2798069C (en) | 2016-07-05 |
| WO2011140203A2 (en) | 2011-11-10 |
| EP2566447A2 (en) | 2013-03-13 |
| US8846641B2 (en) | 2014-09-30 |
| AR081015A1 (es) | 2012-05-30 |
| BR112012028308B1 (pt) | 2021-09-28 |
| KR20130060228A (ko) | 2013-06-07 |
| CN106389325A (zh) | 2017-02-15 |
| WO2011140203A3 (en) | 2012-04-19 |
| ZA201208199B (en) | 2014-01-29 |
| TWI606841B (zh) | 2017-12-01 |
| US20130244971A1 (en) | 2013-09-19 |
| CN102939074A (zh) | 2013-02-20 |
| JP5794744B2 (ja) | 2015-10-14 |
| AU2011248129B2 (en) | 2014-10-09 |
| ES2809304T3 (es) | 2021-03-03 |
| BR112012028308A2 (pt) | 2016-11-01 |
| EP2566447B1 (en) | 2020-07-15 |
| AU2011248129A1 (en) | 2012-11-29 |
| SG185422A1 (en) | 2012-12-28 |
| US20110275593A1 (en) | 2011-11-10 |
| NZ603345A (en) | 2014-12-24 |
| JP2013525493A (ja) | 2013-06-20 |
| TW201141524A (en) | 2011-12-01 |
| KR20180001587A (ko) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012012826A (es) | Formulaciones de galactomanana oftalmicas estabilizadas. | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| MX2013002422A (es) | Sales de lorcaserina con acidos opticamente activos. | |
| IN2014MN02248A (es) | ||
| GB201106743D0 (en) | Novel compounds | |
| AR112286A2 (es) | Sistema polimérico de lágrimas artificiales | |
| ZA201301155B (en) | Ophthalmic drug delivery | |
| EA033171B1 (ru) | Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| GB201106750D0 (en) | Novel compounds | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| WO2013067199A3 (en) | Subcutaneous delivery of polymer conjugates of therapeutic agents | |
| TN2012000261A1 (en) | Aerosol formulation for copd | |
| WO2013171764A3 (en) | Ophthalmic formulations | |
| IL227352A0 (en) | A system for ocular administration of a drug | |
| PT2591785T (pt) | Utilização de 5-androstano(alquilo)-3,5,6-triol na preparação de fármacos neuroprotetores | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| BR112015014137A2 (pt) | unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma | |
| MX2012006265A (es) | Formulaciones disacaridas hipersulfatadas. | |
| GEP20166459B (en) | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol | |
| UA105944C2 (uk) | Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| EP2568990A4 (en) | METHOD OF PRODUCING PLEURODESIS | |
| BR112012020828A2 (pt) | preparado farmacêutico que contém miramistina | |
| GB201110632D0 (en) | Drug delivery formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |